Citations

Clear

6273 citation(s) found for "To, Andrew".

Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review
Blumenfeld, Andrew , Napchan, Uri, Bender, Steven D. , Klein, Brad , Berliner, Randall, Schim, Jack , Friedman, Deborah I. , Young, William B. , Robertson, Carrie E. , Silberstein, Stephen D., Ashkenazi, Avi , Ailani, Jessica , Charleston, Larry , Dodick, David W. , Robbins, Matthew S. , Robertson, Carrie E , Friedman, Deborah I , Klein, Brad C

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 13, 2013 | Volume: 53 | Issue: 3 | Pages: 437-446

10.1111/head.12053 | PMID 23406160 Get It

Objective To describe a standardized methodology for the performance of peripheral nerve blocks ( PNB s) in the treatment of headache disorders. Background PNBs have long been employed in the management of headache disorders, but a wide variety of techniques are utilized in literature reports and clinical practice. Methods The A merican H eadache S ociety S pecial I nterest S ection for PNBs and other I nterventional P rocedures convened meetings during 2010‐2011 featuring formal discussions and agreements about the procedural details for occipital and trigeminal PNBs . A subcommittee then generated a narrative review detailing the methodology. Results PNB indications may include select primary headache disorders, secondary headache disorders, and cranial neuralgias. Special procedural considerations may be necessary in certain patient populations, including pregnancy, the elderly, anesthetic allergy, prior vasovagal attacks, an open skull defect, antiplatelet/anticoagulant use, and cosmetic concerns. PNBs described include greater occipital, lesser occipital, supratrochlear, supraorbital, and auriculotemporal injections. Technical success of the PNB should result in cutaneous anesthesia. Targeted clinical outcomes depend on the indication, and include relief of an acute headache attack, terminating a headache cycle, and transitioning out of a medication‐overuse pattern. Reinjection frequency is variable, depending on the indications and agents used, and the addition of corticosteroids may be most appropriate when treating cluster headache. Conclusions These recommendations from the A merican H eadache S ociety S pecial I nterest S ection for PNBs and other I nterventional P rocedures members for PNB methodology in headache disorder treatment are derived from the available literature and expert consensus. With the exception of cluster headache, there is a paucity of evidence, and further research may result in the revision of these recommendations to improve the outcome and safety of these interventions.
Faculty Opinions recommendation of HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 8, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717964963.793470322 Get It

The Role of Diazepam Loading for the Treatment of Alcohol Withdrawal Syndrome in Hospitalized Patients
Muzyk, Andrew J. , Leung, Jonathan G. , Embury, Eric R., Jones, Sharon, Nelson, Sarah E. , Leung, Jonathan G

Mayo Clinic

The American Journal on Addictions | February 1, 2013 | Volume: 22 | Issue: 2 | Pages: 113-118

10.1111/j.1521-0391.2013.00307.x | PMID 23414495 Get It

BackgroundAlcohol withdrawal accounts for a significant amount of hospital admissions and can quickly progress to the development of delirium tremens (DTs), seizures, and death. Rapid identification and management of alcohol withdrawal syndrome (AWS) is vital and can be managed with a number of different treatment strategies. Diazepam loading is a treatment strategy that utilizes the pharmacokinetics of this agent to achieve a rapid reduction in symptoms followed by sustained benefit over a period of days.ObjectiveThe purpose of this review is to evaluate the role of diazepam loading for AWS.MethodsA literature search of four databases—Pubmed, PsychInfo, Biosis, and Embase—was conducted to identify publications between 1960 and August 2011 that described the use of diazepam loading for the treatment of AWS. Eight trials, both open‐label and controlled trials were identified. Only four randomized controlled‐trials (RCTs) have been published and they are reviewed in this paper.ResultsIncluded trials of hospitalized inpatients found that diazepam loading provided rapid symptom relief as well as reduced the incidence of seizures and duration of DTs. In patients diagnosed with severe DTs, rapidly administered doses of diazepam produced a quick calming effect. While no adverse events resulting from diazepam loading were noted, no formal assessment tool was used to evaluate its safety. Larger randomized controlled‐trials are needed to better evaluate safety outcomes.ConclusionsDiazepam loading is an effective treatment option for hospitalized patients experiencing AWS. Diazepam loading uses the concept of symptom‐triggered therapy, a mainstay of current AWS treatment, while exploiting its prolonged elimination half‐life and eliminating the need for additional pharmacologic therapy. Studies reviewed found diazepam loading significantly improved a number of important outcomes in AWS, including time in DTs, compared to traditional treatment strategies. (Am J Addict 2013;22:113‐118)
Clinicopathologic Predictors of Thyroid Bed Recurrence of Differentiated Thyroid Cancer Using Ultrasound-Guided Fine-Needle Aspiration Biopsies
Adhikari, Laura , Sciallis, Andrew P. , Reynolds, Jordan , Jenkins, Sarah M. , Smith, Carin Y. , Stan, Marius N. , Nassar, Aziza , Nassar, Aziza , Smith, Carin Y , Stan, Marius N , Reynolds, Jordan P

Mayo Clinic

Thyroid | February 1, 2013 | Volume: 23 | Issue: 8 | Pages: 982-988

10.1089/thy.2012.0297 | PMID 23374006 Get It

Striational antibodies in a paraneoplastic context
McKeon, Andrew , Lennon, Vanda A. , Klein, Christopher J. , Pittock, Sean J. , Lachance, Daniel Honore , Pittock, S J , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Muscle & Nerve | January 31, 2013 | Volume: 47 | Issue: 4 | Pages: 585-587

10.1002/mus.23774 | PMID 23463255 Get It

ABSTRACTIntroductionThe clinical significance of striational antibodies (StrAbs) detected in the course of paraneoplastic antibody testing is unknown.MethodsWe compared all 203 striational antibody (StrAb)‐seropositive patients identified (2004–2005) during evaluation for paraneoplastic antibodies with age‐ and sex‐matched seronegative controls.ResultsThymoma and myasthenia gravis (MG) were significantly more common among cases (P<0.0001). Cancers more rarely detected after StrAb detection were adenocarcinoma in 5 patients and sarcoma in 3 patients. All patients who had a cancer identified after StrAb testing had a titer of ≥1:7680 or a coexisting muscle AChR‐binding antibody. Autoimmune disorders more commonly observed among cases (with any StrAb value) included: hypothyroidism; rheumatoid arthritis; and pernicious anemia (all P<0.05).ConclusionsStrAbs may serve as a diagnostic clue for an autoimmune diagnosis. There is a low likelihood of oncological significance in patients with StrAb titers <1:7680 without coexisting paraneoplastic Abs. Muscle Nerve, 2013
Intracranial phosphaturic mesenchymal tumors
Mathis, Derek A., Stehel, Edward J., Beshay, Joseph E., Mickey, Bruce , Folpe, Andrew L. , Raisanen, Jack

Mayo Clinic

Journal of Neurosurgery | January 25, 2013 | Volume: 118 | Issue: 4 | Pages: 903-907

10.3171/2012.12.jns12598 | PMID 23350780 Get It

Hypophosphatemia with osteomalacia may be due to a neoplasm that produces fibroblast growth factor 23 (FGF-23), which inhibits phosphate reabsorption in the kidneys. Most of these tumors occur in bone or soft tissue and occasionally in the head, although intracranial occurrence is very rare. This report describes a tumor that caused hypophosphatemia and osteomalacia and was located entirely in the right anterior cranial fossa. Radiologically, the tumor resembled a meningioma; histologically, it was a low-grade phosphaturic mesenchymal tumor, mixed connective tissue variant (PMTMCT). After gross-total resection, the patient's symptoms abated and laboratory values normalized. The authors also studied another PMTMCT initially diagnosed as a hemangiopericytoma that involved the left anterior cranial fossa and ethmoid sinus, and reviewed reports of 6 other intracranial tumors that induced osteomalacia, 3 entirely in the anterior cranial fossa, 2 involving the anterior cranial fossa and ethmoid sinus, and 1 in the cavernous sinus. In older children or adults who have hypophosphatemia with osteomalacia and no personal or family history of metabolic, renal, or malabsorptive disease, a neoplasm should be suspected and an imaging workup that includes the brain is warranted, with particular attention to the anterior cranial fossa. Additionally, because there are some overlapping histological features between PMTMCTs and hemangiopericytomas, it may be helpful to assess tumoral FGF-23 expression by reverse transcriptase polymerase chain reaction or immunohistochemical analysis in patients with oncogenic osteomalacia from an intracranial tumor diagnosed as, or resembling, hemangiopericytoma.
Chromosomal microarray impacts clinical management
Riggs, Erin Rooney , Wain, Karen E. , Riethmaier, Darlene, Smith‐Packard, Bethanny, Faucett, W. Andrew , Hoppman, Nicole L., Thorland, Erik C., Miller, David T. , Patel, Viren

Mayo Clinic

Clinical Genetics | January 25, 2013 | Volume: 85 | Issue: 2 | Pages: 147-153

10.1111/cge.12107 | PMID 23347240 Get It

Chromosomal microarray analysis (CMA) is standard of care, first‐tier clinical testing for detection of genomic copy number variation among patients with developmental disabilities. Although diagnostic yield is higher than traditional cytogenetic testing, management impact has not been well studied. We surveyed genetic services providers regarding CMA ordering practices and perceptions about reimbursement. Lack of insurance coverage because of perceived lack of clinical utility was cited among the most frequent reasons why CMA was not ordered when warranted. We compiled a list of genomic regions where haploinsufficiency or triplosensitivity cause genetic conditions with documented management recommendations, estimating that at least 146 conditions potentially diagnosable by CMA testing have published literature supporting specific clinical management implications. Comparison with an existing clinical CMA database to determine the proportion of cases involving these regions showed that CMA diagnoses associated with such recommendations are found in approximately 7% of all cases (n = 28,526). We conclude that CMA impacts clinical management at a rate similar to other genetic tests for which insurance coverage is more readily approved. The information presented here can be used to address barriers that continue to contribute to inequities in patient access and care in regard to CMA testing.
Circulating Antibodies and Macrophages as Modulators of Adenovirus Pharmacology
Khare, Reeti , Hillestad, Matthew L. , Xu, Zhili , Byrnes, Andrew P. , Barry, Michael A. , Barry, Michael A

Mayo Clinic

Journal of Virology | January 17, 2013 | Volume: 87 | Issue: 7 | Pages: 3678-3686

10.1128/jvi.01392-12 | PMID 23325678 Get It

ABSTRACT Adenovirus serotype 5 (Ad5) naturally infects the liver after intravenous injection, making it a candidate for hepatocyte-directed gene transfer. While Ad5 can be efficient, most of the dose is destroyed by liver Kupffer cells before it can reach hepatocytes. In contrast, Ad5 bearing the hexon from Ad6 (Ad5/6) evades Kupffer cells. While Ad5/6 dramatically increases hepatocyte transduction in BALB/c mice, it has surprisingly little effect on C57BL/6 mice. To determine the source of this strain-specific difference, the roles of Kupffer cells, liver sinusoidal endothelial cells (LSECs), hepatocytes, scavenger receptors, clotting factors, and immunoglobulins were analyzed. The numbers of Kupffer cells and LSECs, the level of clotting factor X, and hepatocyte infectibility did not differ between different strains of mice. In contrast, high levels of immunoglobulins correlated negatively with Ad5 liver transduction in different mouse strains. Removal of immunoglobulins by use of Rag-deficient mice restored Ad5 transduction to maximal levels. Removal of Kupffer cells by predosing or by testing in colony-stimulating factor knockout mice restored Ad5 transduction in the presence of immunoglobulins. Partial reconstitution of IgM in Rag mice resulted in significant reductions in liver transduction by Ad5 but not by Ad5/6. These data suggest a role for IgM-mediated clearance of Ad5 via Kupffer cells and may explain the mechanism by which Ad5/6 evades these cells. These mechanisms may play a vital role in Ad pharmacology in animals and in humans.
Identification of Inherited Genetic Variations Influencing Prognosis in Early-Onset Breast Cancer
Rafiq, Sajjad , Tapper, William , Collins, Andrew , Khan, Sofia , Politopoulos, Ioannis, Gerty, Sue, Blomqvist, Carl , Nevanlinna, Heli , Liu, Jianjun , Eccles, Diana , Couch, Fergus J. , Nevanlinna, H , Eccles, Diana , Liu, Jing

Mayo Clinic

Cancer Research | January 14, 2013 | Volume: 73 | Issue: 6 | Pages: 1883-1891

10.1158/0008-5472.can-12-3377 | PMID 23319801 Get It

Abstract Genome-Wide Association Studies (GWAS) have begun to investigate associations between inherited genetic variations and breast cancer prognosis. Here, we report our findings from a GWAS conducted in 536 patients with early-onset breast cancer aged 40 or less at diagnosis and with a mean follow-up period of 4.1 years (SD = 1.96). Patients were selected from the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer. A Bonferroni correction for multiple testing determined that a P value of 1.0 × 10−7 was a statistically significant association signal. Following quality control, we identified 487,496 single nucleotide polymorphisms (SNP) for association tests in stage 1. In stage 2, 35 SNPs with the most significant associations were genotyped in 1,516 independent cases from the same early-onset cohort. In stage 2, 11 SNPs remained associated in the same direction (P ≤ 0.05). Fixed effects meta-analysis models identified one SNP associated at close to genome wide level of significance 556 kb upstream of the ARRDC3 locus [HR = 1.61; 95% confidence interval (CI), 1.33–1.96; P = 9.5 × 10−7]. Four further associations at or close to the PBX1, RORα, NTN1, and SYT6 loci also came close to genome-wide significance levels (P = 10−6). In the first ever GWAS for the identification of SNPs associated with prognosis in patients with early-onset breast cancer, we report a SNP upstream of the ARRDC3 locus as potentially associated with prognosis (median follow-up time for genotypes: CC = 4 years, CT = 3 years, and TT = 2.7 years; Wilcoxon rank-sum test CC vs. CT, P = 4 × 10−4 and CT vs. TT, P = 0.76). Four further loci may also be associated with prognosis. Cancer Res; 73(6); 1883–91. ©2012 AACR.
Proteolysis Breaks Tolerance toward Intact α345(IV) Collagen, Eliciting Novel Anti–Glomerular Basement Membrane Autoantibodies Specific for α345NC1 Hexamers
Olaru, Florina, Wang, Xu-Ping, Luo, Wentian, Ge, Linna, Miner, Jeffrey H. , Kleinau, Sandra , Geiger, Xochiquetzal J., Wasiluk, Andrew, Heidet, Laurence , Kitching, A. Richard , Borza, Dorin‐Bogdan , Kitching, A Richard

Mayo Clinic

The Journal of Immunology | January 10, 2013 | Volume: 190 | Issue: 4 | Pages: 1424-1432

10.4049/jimmunol.1202204 | PMID 23303673 Get It

Abstract Goodpasture disease is an autoimmune kidney disease mediated by autoantibodies against noncollagenous domain 1 (NC1) monomers of α3(IV) collagen that bind to the glomerular basement membrane (GBM), usually causing rapidly progressive glomerulonephritis (GN). We identified a novel type of human IgG4-restricted anti–GBM autoantibodies associated with mild nonprogressive GN, which specifically targeted α345NC1 hexamers but not α3NC1 monomers. The mechanisms eliciting these anti–GBM autoantibodies were investigated in mouse models recapitulating this phenotype. Wild-type and FcγRIIB−/− mice immunized with autologous murine GBM NC1 hexamers produced mouse IgG1-restricted autoantibodies specific for α345NC1 hexamers, which bound to the GBM in vivo but did not cause GN. In these mice, intact collagen IV from murine GBM was not immunogenic. However, in Col4a3−/− Alport mice, both intact collagen IV and NC1 hexamers from murine GBM elicited IgG Abs specific for α345NC1 hexamers, which were not subclass restricted. As heterologous Ag in COL4A3-humanized mice, murine GBM NC1 hexamers elicited mouse IgG1, IgG2a, and IgG2b autoantibodies specific for α345NC1 hexamers and induced anti–GBM Ab GN. These findings indicate that tolerance toward autologous intact α345(IV) collagen is established in hosts expressing this Ag, even though autoreactive B cells specific for α345NC1 hexamers are not purged from their repertoire. Proteolysis selectively breaches this tolerance by generating autoimmunogenic α345NC1 hexamers. This provides a mechanism eliciting autoantibodies specific for α345NC1 hexamers, which are restricted to noninflammatory IgG subclasses and are nonnephritogenic. In Alport syndrome, lack of tolerance toward α345(IV) collagen promotes production of alloantibodies to α345NC1 hexamers, including proinflammatory IgG subclasses that mediate posttransplant anti–GBM nephritis.